Leishmaniasis
Leishmaniasis is a vector-borne disease caused by protozoan parasites of the genus Leishmania, transmitted to humans through the bites of infected female phlebotomine sandflies. The disease manifests in diverse clinical forms, ranging from localized skin ulcers to life-threatening systemic infections. The pathogenesis involves the inoculation of promastigote forms into the skin, where they are phagocytosed by macrophages and transform into amastigotes, replicating intracellularly and evading host immune responses. The spectrum of disease reflects the interplay between parasite species and host immune status, with cellular immunity playing a crucial role in disease outcome. Health impacts are profound, including chronic morbidity, disfigurement, disability, and in visceral forms, significant mortality if untreated. Leishmaniasis is also associated with social stigma, economic burden, and increased vulnerability in affected populations.
Cutaneous leishmaniasis is the most common form of the disease, characterized by one or more ulcerative skin lesions at the site of sandfly bites. These lesions can be painless or painful, often with raised borders and a central crater, and may heal spontaneously over months to years, sometimes leaving disfiguring scars. The clinical presentation varies depending on the Leishmania species involved, with some causing simple localized ulcers and others resulting in diffuse or disseminated cutaneous disease. Secondary bacterial infection can complicate lesions, and psychosocial impact due to visible scarring is considerable.
Mucocutaneous leishmaniasis is a severe form primarily caused by Leishmania species in the Viannia subgenus, notably L. braziliensis. It typically follows cutaneous infection, sometimes emerging months or years after the initial skin lesion. The disease involves destructive lesions of the mucous membranes of the nose, mouth, and throat, leading to tissue destruction, disfigurement, and functional impairment. Mucocutaneous involvement is often progressive and may require complex medical and surgical management.
Visceral leishmaniasis, also known as kala-azar, is the most severe form and is caused mainly by L. donovani and L. infantum (L. chagasi in the New World). The disease is characterized by systemic infection of the reticuloendothelial system, presenting with prolonged fever, weight loss, hepatosplenomegaly, pancytopenia, and hypergammaglobulinemia. Without treatment, visceral leishmaniasis is almost always fatal. Immunosuppressed individuals, such as those with HIV, are at increased risk of severe disease and relapse.
Leishmaniasis is endemic in more than 90 countries across tropical, subtropical, and temperate regions, affecting an estimated 12 million people worldwide. The World Health Organization estimates that 700,000 to 1 million new cases occur annually, with approximately 20,000 to 30,000 deaths, mostly due to visceral leishmaniasis. The disease burden is highest in South Asia, East Africa, and South America. Risk factors include poverty, malnutrition, population displacement, poor housing, and environmental changes that favor sandfly breeding. Both zoonotic and anthroponotic transmission cycles exist, with dogs and other mammals serving as important reservoirs in many regions. Coinfection with HIV significantly increases susceptibility and complicates management, particularly in endemic areas.
Diagnosis of leishmaniasis relies on a combination of clinical assessment, epidemiological context, and laboratory confirmation. Parasitological diagnosis involves direct demonstration of Leishmania amastigotes in tissue smears, biopsies, or aspirates from skin lesions, bone marrow, spleen, or lymph nodes, using microscopy with Giemsa or other stains. Culture of the parasite in specialized media and molecular methods such as polymerase chain reaction (PCR) provide increased sensitivity and species identification. Serological tests, including the direct agglutination test (DAT) and the rK39 immunochromatographic assay, are valuable for the diagnosis of visceral leishmaniasis but are less reliable for cutaneous forms. Additional laboratory investigations may include complete blood counts, liver and renal function tests, and immunological assays. Diagnosis should be confirmed before initiating specific therapy, and differential diagnoses such as other ulcerative skin diseases, hematological disorders, or opportunistic infections should be considered.
Amphotericin B lipid complex is utilized as an antifungal and antiprotozoal agent for the treatment of leishmaniasis, offering improved tolerability compared to conventional amphotericin B formulations. Liposomal amphotericin B and liposome-encapsulated amphotericin B are advanced formulations that enhance drug delivery to infected tissues and reduce nephrotoxicity, and are indicated for the treatment of visceral leishmaniasis. Hexadecylphosphocholine, also known as miltefosine, is an oral agent effective against various forms of leishmaniasis and represents a significant advance due to its oral route of administration. Pentamidine isethionate is another antiprotozoal drug used in the management of leishmaniasis, particularly in cases where first-line treatments are contraindicated or ineffective. Aminosidine, also referred to as paromomycin, is an aminoglycoside antibiotic employed in the treatment of leishmaniasis, often as an intramuscular or topical agent. Amphotericin B deoxycholate is a traditional formulation of amphotericin B that remains a standard therapy for visceral leishmaniasis, though its use may be limited by toxicity. Meglumine antimoniate, known as protostib, is a pentavalent antimonial compound administered parenterally for cutaneous and visceral leishmaniasis. Sodium stibogluconate is another pentavalent antimonial agent, widely used as a first-line treatment in many endemic regions for both cutaneous and visceral forms of the disease.
| Structure | Generic Name | CAS Registry Number | Molecular Formula | Molecular Weight |
|---|---|---|---|---|
| amphotericin B lipid complex; liposomal amphotericin B; liposome-encapsulated amphotericin B | ||||
 | hexadecylphosphocholine; miltefosine (Rec INN; BAN) | 58066-85-6 | C21 H46 N O4 P | 407.568 |
| liposomal amphotericin B | ||||
 | pentamidine isethionate (Rec INN; USAN; BAN) | 100-33-4 (free base); 140-64-7 | C19 H24 N4 O2 . 2 C2 H6 O4 S | 592.683 |
 | aminosidine; paromomycin (Rec INN; USAN; BAN) | 7542-37-2 | C23 H45 N5 O14 . H2 O4 S | 713.707 |
 | amphotericin (BAN); amphotericin B (Rec INN; JAN); amphotericin B Deoxycholate | 1397-89-3 | C47 H73 N O17 | 924.079 |
 | meglumine antimoniate; protostib | C7 H18 N O5 . O3 Sb | 365.98 | |
 | sodium stibogluconate | 16037-91-5 | C12 H18 O17 Sb2 . 3 Na . 9 H2 O | 908.888 |
Make Order
Experimental Scheme
Implementation
Conclusion
